CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
CVN424 150 mg +1 moredrug
Likely dose
CVN424 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06006247
NCT06006247Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Trial of CVN424 in Early Parkinson's Disease

Cerevance Beta, Inc.·interventional·Posted Aug 23, 2023·Updated Mar 23, 2026

In Brief

A Phase 2 clinical trial evaluating CVN424 150 mg and Placebo for Parkinson's Disease. Completed, enrolled 64 participants across 42 sites.

Detailed Summary

This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not taking dopaminergic or anti-PD therapies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedAug 23, 2023
Enrollment StartSep 11, 2023
Primary CompletionJan 30, 2025
Study CompletionFeb 13, 2025
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 2.9 years ago

Interventions

CVN424 150 mgdrug

Participants will receive 1 CVN424 tablet (150 mg) per day.

Placebodrug

Participants will receive 1 matching placebo tablet per day.